Precigen, Inc. (PGEN): Price and Financial Metrics
PGEN Price/Volume Stats
| Current price | $1.33 | 52-week high | $1.88 |
| Prev. close | $1.32 | 52-week low | $0.84 |
| Day low | $1.28 | Volume | 1,013,395 |
| Day high | $1.34 | Avg. volume | 1,076,162 |
| 50-day MA | $1.46 | Dividend yield | N/A |
| 200-day MA | $1.35 | Market Cap | 331.06M |
PGEN Stock Price Chart Interactive Chart >
Precigen, Inc. (PGEN) Company Bio
Precigen, Inc. (formerly Intrexon Corporation) provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. The company was founded in 1998 and is based in Germantown, Maryland.
Latest PGEN News From Around the Web
Below are the latest news stories about PRECIGEN INC that investors may wish to consider to help them evaluate PGEN as an investment opportunity.
Even after rising 15% this past week, Precigen (NASDAQ:PGEN) shareholders are still down 86% over the past three yearsPrecigen, Inc. ( NASDAQ:PGEN ) shareholders should be happy to see the share price up 16% in the last month. But the... |
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare ConferencePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 5:15 PM PT/8:15 PM ET in San Francisco, California. |
5 ‘Jackpot’ Stocks to Buy for 2024 for 10X GainsThese stocks to buy have the potential to take your portfolio to the next level thanks to the cutting-edge technology they represent. |
Precigen to Participate in the JMP Securities Hematology and Oncology SummitPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 3:00 PM ET. |
3 Penny Stocks to Buy to Turn $1 into $100: November 2023Are you looking for outsized gains for your portfolio. |
PGEN Price Returns
| 1-mo | -7.64% |
| 3-mo | 3.91% |
| 6-mo | 25.47% |
| 1-year | 14.66% |
| 3-year | -83.04% |
| 5-year | -67.64% |
| YTD | -0.75% |
| 2023 | -11.84% |
| 2022 | -59.03% |
| 2021 | -63.63% |
| 2020 | 86.13% |
| 2019 | -16.21% |
Loading social stream, please wait...